On May 6, 2024, Cellectis S.A., closed the transaction. As the result of the transaction, AstraZeneca PLC, now owns approximately 44% of the share capital and 30% of the voting rights of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,510 GBX | +0.95% | -0.37% | +18.02% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,510 GBX | +0.95% | -0.37% | 246B | ||
1.95 EUR | -7.36% | -17.37% | 209M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.02% | 246B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B | |
-3.71% | 116B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC